New trends in medicinal chemistry approaches to antiobesity therapy

Current Topics in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 564-596

  Lee, Jinhwa ^a   Song, Kwang Seop ^a   Kang, Jahyo ^b   Lee, Suk Ho ^a   Lee, Junwon ^a  

^a Green Cross Company   (South Korea)

^b Sogang University   (South Korea)

Author keywords

Aminergic receptor modulator; Antiobesity; CB1; MC4R; MCH1R; Neuropeptide Y family

Indexed keywords

1,3,4 TRISUBSTITUTED 2 OXOPIPERAZINE DERIVATIVE; 2 [1 (3 CHLORO 5 ISOPROPOXYCARBONYLAMINOPHENYL)ETHYLAMINO] 6 [2 (5 ETHYL 4 METHYL 2 THIAZOLYL)ETHYL] 4 MORPHOLINOPYRIDINE; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; AMFEBUTAMONE; ANTIOBESITY AGENT; AVE 1625; BIARYLPYRAZOLYL OXADIAZOLE DERIVATIVE; BIM 28163; CANNABINOID 1 RECEPTOR ANTAGONIST; CP 945598; ELIXIR 57; GHRELIN RECEPTOR ANTAGONIST; J 104870; JMV 3002; L 692400; MELANOCORTIN 4 RECEPTOR AGONIST; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; OPIATE ANTAGONIST; PLACEBO; RIMONABANT; SEROTONIN 2C AGONIST; SEROTONIN 6 ANTAGONIST; SIBUTRAMINE; TARANABANT; TETRAHYDROLIPSTATIN; TM 30338; TZP 301; UNCLASSIFIED DRUG; UNINDEXED DRUG; YIL 870;

BINDING AFFINITY; BODY COMPOSITION; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ENERGY BALANCE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROGEN BOND; IC 50; INSULIN RELEASE; LIPID METABOLISM; MENTAL DISEASE; NONHUMAN; OBESITY; OXIDATION; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; OBESITY;

EID: 68949216617     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788897853     Document Type: Review

References (251)

1. Szmitko, P. E.; Verma, S. The endocannabinoid system and cardiometabolic risk. Atherosclerosis 2008, 199(2), 248-256.
2. Wang, J.; Ueda, N. Role of the endocannabinoid system in metabolic control. Curr. Opin. Nephrol. Hypertens. 2008, 17, 1-10.
3. Xie, S.; Furjanic, M. A.; Ferrara, J. J.; McAndrew, N. R.; Ardino, E. L.; Ngondara, A.; Bernstein, Y.; Thomas, K. J.; Kim, E.; Walker, J. M.; Nagar, S.; Ward, S. J.; Raffa, R. B. The endocannabinoid system and rimonabant: A new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use. J. Clin. Pharm. Ther. 2007, 32, 209-231.
4. Pagotto, U.; Vicennati, V.; Pasquali, R. The endocannabinoid system and the treatment of obesity. Ann. Med. 2005, 37, 270-275.
5. Bellocchio, L.; Mancini, G.; Vicennati, V.; Pasquali, R.; Pagotto, U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr. Opin. Pharmacol. 2006, 6(6), 586-591.
6. Kunos, G. Understanding metabolic homeostasis and imbalance: What is the role of the endocannabinoid system? Am. J. Med. 2007, 120(9A), S18-S24.
7. Kyrou, I.; Valsamakis, G.; Tsigos, C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann. N. Y. Acad. Sci. 2006, 1083, 270-305.
8. Cervino, C.; Pasquali, R.; Pagotto, U. Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches. Mini. Rev. Med. Chem. 2007, 7(1), 21-30.
9. Fremming, B. A.; Boyd, S. T. Taranabant, a novel cannabinoid type 1 receptor inverse agonist. Curr. Opin. Investig. Drugs, 2008, 9(10), 1116-1129.
10. Kim, M.; Kim, J. Y.; Song, K. S.; Kim, J.; Lee, J. Convenient total synthesis of taranabant (MK-0364), a novel cannabinoid-1 receptor inverse agonist as an anti-obesity agent. Tetrahedron, 2007, 63(52), 12845-12852.
11. Barth, F. CB1 cannabinoid receptor antagonists. Ann. Rep. Med. Chem. 2005, 40, 103-118.
12. Lee, S. H.; Seo, H. J.; Lee, S.-H.; Jung, M. E.; Park, J.-H.; Park, H.-J.; Yun, H.; Na, J.; Kang, S. Y.; Song, K.-S.; Kim, M.; Chang, C.-H.; Kim, J.; Lee, J. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. J. Med. Chem. 2008, 51(22), 7216-7233.
13. Jones, D. End of the line for cannabinoid receptor 1 as an antiobesity target? Nat. Rev. Drug Discov. 2008, 7(12), 961-962.
14. Gantz, I.; Fong, T. M. The melanocortin system. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E468-E474.
15. Ujjainwalla, F.; Sebhat, I. K. Small molecule ligands of the human melanocortin-4 receptor. Curr. Top. Med. Chem. 2007, 7, 1068-1084.
16. Emmerson, P. J.; Fisher. M. J.; Yan, L. Z.; Mayer, J. P. Melanocrotin-4 receptor agonists for the treatment of obesity. Curr. Top. Med. Chem. 2007, 7, 1121-1130.
17. Nargund, R. P.; Strack, A. M.; Fong, T. M. Melanocortion-4 receptor (MC4R) agonists for the treatment of obesity. J. Med. Chem. 2006, 49, 4035-4043.
18. Tian, X.; Switzer, A. G.; Derose, S. A.; Mishra, R. K.; Solinsky, M. G.; Mumin, R. N.; Ebetino, F. H.; Jayasinghe, L. R.; Webster, M. E.; Colson, A.-O.; Crossdoersen, D.; Pinney, B. B.; Farmer, J. A.; Dowty, M. E.; Obringer, C. M.; Cruze, C. A.; Burklow, M. L.; Suchanek, P. M.; Dong, L.; Dirr. M. K.; Sheldon, R. J.; Wos, J. A. Discovery of orally bioavaiable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents. J. Med. Chem. 2008, 51, 6055-6066.
19. Hess, S.; Linde, Y.; Ovadia, O.; Safrai, E.; Shalev, D. E.; Swed, A.; Halbfinger, E.; Lapidot, T.; Winkler, I.; Gabinet, Y.; Faier, A.; Yarden, D.; Xiang, Z.; Portillio, F. P.; Haskell-Luevano, C.; Gilon, C.; Hoffman, A. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J. Med. Chem. 2009, 51, 1026-1034.
20. Bakshi, R. K.; Dellureficio, J. P.; Hong, Q.; Jian, T.; Liu, J.; Nargund, R. P.; Ye, Z. Acylated piperidine derivatives as melanocortin-4 receptor modulators. WO2008039418, 2008.
21. Herzner, H.; Hoffman-Enger, B.; Lescop, C.; Soeberdt, M.; Deppe, H.; Weyerman, P.; Nordhoff, S.; Bulat, S.; Von Sprecher, A.; Feurer, A. Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. WO2009015867, 2009.
22. Lely, A. J.; Tschop, M.; Heiman, M. L.; Ghigo, E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 2004, 25(3), 426-457.
23. Cummings, D. E.; Foster-Schubert, K. E.; Over, J. Ghrelin and energy balance: Focus on current controversies. Curr. Drug Targets 2005, 6(2), 153-169.
24. Higgins, S. C.; Gueorguiev, M.; Korbonits, M. Ghrelin, the peripheral hunger hormone. Ann. Med. 2007, 39, 116-136.
25. Soares, J. B.; Roncon-Albuquerque, R. Jr.; Leite-Moreira, A. Ghrelin and ghrelin receptor inhibitors: Agents in the treatment of obesity. Expert Opin. Ther. Targets 2008, 12(9), 1177-1189.
26. Kobelt, P.; Helmling, S.; Stengel, A.; Wlotzka, B.; Andresen, V.; Klapp, B. F.; Wiedenmann, B.; Klussmann, S.; Monnikes, H. Antighrelin spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut 2006, 55(6), 788-792.
27. Katergari, S. A.; Milousis, A.; Pagonopoulou, O.; Asimakopoulos, B.; Nikolettos, N. K. Ghrelin in pathological conditions. Endocr. J. 2008, 55(3), 439-453.
28. Horvath, T. L.; Castañeda, T.; Tang-Christensen, M.; Pagotto, U.; Tschöp, M. H. Ghrelin as a potential anti-obesity target. Curr. Pharm. Des. 2003, 9(17), 1383-1395.
29. Tschöp, M.; Smiley. D. L.; Heiman, M.L. Ghrelin induces adiposity in rodents. Nature, 2000, 123, 1120-1128.
30. Nakazato, M.; Murakami, N.; Date, Y.; Kojima, M.; Matsuo, H.; Kangawa, K. A role for ghrelin in the central regulation of feeding. Nature 2001, 409, 194-198.
31. Pusztai, P.; Sarman, B.; Ruzicska, E.; Toke, J.; Racz, K.; Somogyi, A.; Tulassay, Z. Ghrelin: A new peptide regulating the neurohormonal system, energy homeostasis and glucose metabolism. Diabetes Metab. Res. Rev. 2008, 24, 343-352.
32. Hofbauer, K. G.; Nicholson, J. R.; Boss, O. The obesity epidemic: current and future pharmacological treatments. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 565-592.
33. Moulin, A.; Ryan, J.; martinez, J.; Fehrentz, J-A. Recent developments in ghrelin receptor ligands. ChemMedChem, 2007, 2, 1242-1259.
34. Deghenghi, R. (Zentaris) Ghrelin antagonists. WO02008250, 2002.
35. Halem, H. A.; Taylor, J. E.; Dong, J. Z.; Shen, Y.; Datta, R.; Abizaid, A.; Diano, S.; Horvath, T.; Zizzari, P.; Bluet-Pajot, M.-T.; Epelbaum, J.; Culler, M. D. Novel analogs of ghrelin: Physiological and clinical implications. Eur. J. Endocrinol. 2004, 151, S71-S75.
36. Fraser, G.; Hoveyda, H. (Tranzyme Pharma) Macrocyclic ghrelin receptor antagonists and inverse agonists ans methods of using the same. WO2006137974, 2006.
37. Deslongchamps, P.; Dory, Y.; Peterson, M.; Benakli, K.; Marsault, E.; Ouellet, L.; Ramaseshan, M.; Vezina, M.; Fortin, D.; Lan, R.; Li, S.; Villeneuve, G.; Hoveyda, H.; Beaubien, S. Spatially-defined macrocyclic compounds useful for drug discovery. WO2005012331, 2005.
38. Bowere, C. Y.; Tannenbaum, G. S.; Coy, D. H. Ghrelin/growth hormaone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof. WO2007127457, 2007.
39. Andersen, B.; Ankersen, M.; Raun, K. Functional GHS-R antagonists. WO2005114180, 2005.
40. Chen, X.; Connors, R. V.; Dai, K.; Fu, Y.; Jaen, J. C.; Kim, Y-J.; Li, L.; Lizarzaburu, M. E.; Mihalic, J. T.; Shuttleworth, S. J. Substituted benzofused heterocycles. WO2006020959, 2006.
41. Cheng, K.; Chan, W. W. S.; Butler, B.; Wei, L.; Smith, R. G. A novel non-peptidyl growth hormone secretagogue. Horm. Res. 1993, 40, 109-115.
42. Serby, M. D.; Zhao, H.; Szczepankiewicz, B. G.; Kosogof, C.; Xin, Z.; Liu, B.; Liu, M.; Nelson, L. T. J.; Kaszubska, W.; Falls, H. D.; Schaefer, V.; Bush, E. N.; Shapiro, R.; Droz, B. A.; Knourrek-Segel, V. E.; Fey, T. A.; Brune, M. E.; Beno, D. W. A.; Turner, T. M.; Collins, C. A.; Jacobson, P. B.; Sham, H. L.; Liu, G. 2,4-Diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J. Med. Chem. 2006, 49(8), 2568-2578.
43. Xin, Z.; Serby, M. D.; Zhao, H.; Kosogof, C.; Szczepankiewicz, B. G.; Liu, M.; Hutchins, C. W.; Sarris, K. A.; Hoff, E. D.; Falls, H. D.; Lin, C. W.; Ogiela, C. A.; Collins, C. A.; Brune, M. E.; Bush, E. N.; Droz, B. A.; Fey, T. A.; Knourrek-Segel, V. E.; Shapiro, R.; Jacobson, P. B.; Beno, D. W.; Turner, T. M.; Sham, H. L.; Liu, G. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonist. J. Med. Chem. 2006, 49(15), 4459-4469.
44. Hepworth, D.; Carpino, P. A.; Black, S. C. Centrally acting anti-obesity agents. Ann. Rep. Med. Chem. 2006, 41, 77-97.
45. Esler, W. P.; Rudolph, J.; Claus, T. H.; Tang, W.; Barucci, N.; Brown, S.-E.; Bullock, W.; Daly, M.; DeCarr, L.; Li, Y.; Milardo, L.; Molstad, D.; Zhu, J.; Gardell, S. J.; Livingstone, J. N.; Sweet, L. J. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote. Endocrinology 2007, 148(11), 5175-5185.
46. Rudolph, J.; Esler, W. P.; O'Connor, S.; Coish, P. D. G.; Wickens, P. L.; Brands, M.; Bierer, D. E.; Bloomquist, B. T.; Bondar, G.; Chen, L.; Chuang, C.-Y.; Claus, T. H.; Fathi, Z.; Fu, W.; Khire, U. R.; Kristie, J. A.; Liu, X.-G.; Lowe, D. B.; McClure, A. C.; Michels, M.; Ortiz, A. A.; Ramsden, P. D.; Schoenleber, R. W.; Shelenkhin, T. E.; Vakalopoulos, A.; Tang, W.; Wang, L.; Yi, L.; Gardell, S. J.; Livingstone, J. N.; Sweet, L. J.; Bullock, W. H. Quinazolinone derivatives as orally available ghrelin antagonists for the treatment of diabetes and obesity. J. Med. Chem. 2007, 50(21), 5202-5216.
47. Watson, A.; Distefano, P.; Geesaman, B. J. Ghrelin modulating compounds and combinations thereof. WO08141189, 2008.
48. Moulin, A.; Demange, L.; Ryan, J.; Mousseaux, D.; Sanchez, P.; Bergé, G.; Gagne, D.; Perrissoud, D.; Locatelli, V.; Torsello, A.; Galleyrand, J. C.; Fehrentz, J. A.; Martinez, J. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. sythesis and pharmacological in vitro and in vivo evaluations. J. Med. Chem. 2008, 51(3), 689-693.
49. Linnanen, T.; Rist, Ø,; Grimstrup, M.; Frimurer, T.; Hoegberg, T.; Nielsen, F. E.; Gerlach, L-O. Ghrelin receptor modulators. WO08092681, 2008.
50. Ge, M.; Cline, E.; Yang, L.; Mills, S. G. Substituted pyrazoles as ghrelin receptor antagonists. WO2008008286, 2008.
51. Burstein, E.; Eeg Knapp, A.; Olsson, R.; Eskildsen, J.; Ek, F. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof. WO2007079239, 2007.
52. Becskei, C.; Bilik, K. U.; Klussmann, S.; Jarosch, F.; Lutz, T. A.; Riediger, T. The anti-ghrelin Spiegelmer NOX-B11-3 blocks ghrelin-but not fasting-induced neuronal activation in the hypothalamic arcuate. J. Neuroendocrinol. 2008, 20, 85-92.
53. Helmling, S.; Maasch, C.; Eulberg, D.; Buchner, K.; Schröder, W.; Lange, C.; Vonhoff, S.; Wlotzka, B.; Tschöp, M. H.; Rosewicz, S.; Klussmann, S. Inhibition of ghrelin action in vitro and in vivo by a RNA-Spiegelmer. Proc. Natl. Acad. Sci. USA 2004, 101(36), 13174-13179.
54. Shearman, L. P.; Wang, S-P.; Helmling, S.; Stribling, S.; Mazur, P.; Ge, L.; Wang, L.; Klussmann, S.; Macintyre, D. E.; Howard, A. D.; Starck, A. M. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006, 147(3), 1517-1526.
55. Marquis, D. M.; Vasserot, A. P.; Witcher, D. R. Humanized anti-ghrelin antibodies. WO2006091381, 2006.
56. Tatemoto, K.; Cariquist, M.; Mutt, V. Neuropeptide Y. A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296, 659-660.
57. Allen, Y. S.; Adrian, T. E.; Allen, J. M.; Tatemoto, K.; Crow, J.; Bloom, S. R.; Polak, J. M. Neuropeptide Y distribution in the rat brain. Science 1983, 221, 877-879.
58. O'Donohue, T. L.; Chronwall, B. M.; Pruss, R. M.; Mezey, E.; Kiss, J. Z.; Eiden, L. E.; Massari, V. J.; Tessel, R. E.; Pickel, V. M.; Dimaggio, D. A.; Hotchkiss, W. R.; Crowley, W. R.; Zukowska-Grojec, Z. Neuropeptide Y and peptide YY neuronal and endocrine systems. Peptides 1985, 6, 755-768.
59. Wahlestedt, C.; Reis, D. J. Neuropeptide Y-related peptides and their receptors are the receptors potential therapeutic drug targets? Annu. Rev. Pharmacol. Toxicol. 1993, 33, 309-352.
60. Grundemar, L.; Hakanson, R. Multiple neuropeptide Y receptors are involved in cardiovascular regulation. Peripheral and central mechanisms. Gen. Pharmacol. 1993, 24, 785-796.
61. Lundberg, J. M.; Franco-Cerecada, A.; Lacroix, J. S.; Pernow, J. Neuropeptide Y and sympathetic neurotransmission. Ann. N. Y. Acad. Sci. 1990, 611, 166-174.
62. McDermott, B. J.; Millat, B. C.; Piper, H. M. Cardiovascular effects of neuropeptide Y: Receptor interactions and cellular mechanisms. Cardiovasc. Res. 1993, 27, 893-905.
63. Kalra, S. P.; Dube, M. G.; Sahu, A.; Phelps, C. P.; Kalra, P. S. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc. Natl. Acad. Sci. USA 1991, 88, 10931-10935.
64. White, J. D.; Olchovsky, D.; Kershaw, M.; Berelowitz, M. Increased hypothalamic contents of preproneuropeptide-Y messenger ribonucleic acid in streptozotocin-diabetic rats. Endocrinology 1990, 126, 765-772.
65. Sanacora, G.; Kershaw, M.; Finkelstein, J. A.; White, J. D. Increased hypothalamic content of preproneuropeptide Y messenger ribonucleic acid in genetically obese zucker rats and its regulation by food deprivation. Endocrinology 1990, 127, 730-737.
66. Kesterson, R. A.; Huszar, D.; Lynch, A. A.; Simerly, R. B.; Cone, R. D. Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol. Endocrinol. 1997, 11, 630-637.
67. Guan, X.-M.; Yu, H.; Van der Ploeg, L. H. T. Evidence of altered hypothalamic pro-opiomelanocortin/neuropeptide Y mRNA expression in tubby mice. Mol. Brain Res. 1998, 59, 273-279.
68. Egawa, M.; Yoshimatsu, H.; Bray, G. A. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am. J. Physiol. 1991. 260, R328-R334.
69. Jolicoeur, F. B.; Michaud, J. N.; Rivest, R. Menard, D, Gaudin, D.; Fournier, A.; St-Pierre, S. Neurobehavioral profile of neuropeptide Y. Brain Res. Bull. 1991, 26, 265-268.
70. Stanley, B. G.; Kyrkoulim, S. E.; Lampert, S.; Leibowitz, S. F. Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986, 7, 1189-1192.
71. Zarjevski, N.; Cusin, I.; Vettor, R.; Rohner-Jeanrenaud, F.; Jeanrenaud, B. Chronic Intracerebroventricular Neuropeptide-Y Administration to Normal Rats Mimics Hormonal and Metabolic Changes of Obesity. Endocrinology 1993, 133, 1753-1758.
72. Erikson, J. C.; Hollopeter, G.; Palmiter, R. D. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996, 274, 1704-1707.
73. Blomqvist, A. G.; Herzog, H. Y-receptor subtypes-how many more? Trends Neurosci. 1997, 20, 294-298.
74. Bromee, T,; Sjodin, P.; Fredriksson, R.; Boswell, T.; Larsson, T. A.; Salaneck, E.; Zoorob, R.; Mohell, N.; Larhammar, D. Neuropeptide Y-family receptors Y6 and Y7 in chicken, Cloning, Pharmacological characterization, tissue distribution and conserved syntenyl with human chromosome region. FEBS J. 2009, 273, 2048-2063.
75. Batterham, R. L.; Cowley, M. A.; Small, C. J.; Herzog, H.; Cohen, M. A.; Dakin, C. L.; Weren, A. M.; Brynes, A. E.; Low, M. J.; Ghatei, M. A.; Cone, R. D.; Bloom, S. R. Gut hormone PYY (3-36) physiologically inhibits food intake. Nature 2002, 418, 650-654
76. Katsuura, G.; Asakawa, A.; Inui, A. Roles of pancreatic polypeptide in regulation of food intake. Peptides 2002, 23, 323-329.
77. Kanatani, A.; Ishihara, A.; Ashai, S.; Tanaka, T.; Ozaki, S.; Ihara, M. Potent neuropeptide Y Y1 receptor antagonist, 1229U91; blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 1996, 137, 3177-3182.
78. Larsen, P. J.; Tang-Christensen, M.; Stidsen, C. E.; Madsen, K.; Smith, M. S.; Cameron, J. L. Activation of central neuropeptide Y Y1 receptors potently stimulates food intake in male rhesus monkeys. J. Clin. Endocrinol. Metab. 1999, 84, 3781-3791.
79. Balasubramaniam, A.; Dhawan, V. C.; Mullins, D. E.; Chance, W. T.; Sheriff, S.; Guzzi, M.; Prabhakaren, M.; Parker, E. M. Highly selective and potent neuropeptide Y Y1 receptor antagonists based on [Pro, Tyr, Leu]NPY(28-36)-NH (BW1911U90). J. Med. Chem. 2001, 44, 1479-1482.
80. Doods, H. N.; Wieland, H. A.; Engel, W.; Eberlein, W.; Willim, K. D.; Entzeroth. M.; Wienen, W.; Rudolf, K. BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: A review of its pharmacological properties. Regul. Pept. 1996, 65, 71-77.
81. Engstom, M.; Wurster, S.; Savola, J-M.; Panula, P. F. Functional properties of PFR(Tic)amide and BIBP3226 at human neuropeptide FF2 receptors. Peptides 2003, 24, 1947-1954.
82. Wieland, H. A.; Engel, W.; Eberlein, W.; Rudolf, K.;, Doods, H. N. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO3304 and its effect on feeding in rodents. Br. J. Pharmacol. 1998, 125, 549-555.
83. Bristol-Myers Squibb Co. Alkylamine derivatives of dihydropyridine NPY antagonists. US20026479482B2, 2002.
84. Bristol-Myers Squibb Co. Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists. US20036596724B2, 2003.
85. Poindexter, G. S.; Bruce, M. A.; Breitenbucher, J. G.; Higgins, M. A.; Sit, S. Y.; Romine, J. L.; Martin, S. W.; Ward, S. A.; McGovern, R. T.; Clarke, W.; Russell, J.; Antal-Zimanyi, I. Dihydropyridine neuropeptide Y Y1 receptor antagonists 2. bioisosteric urea replacements. Bioorg. Med. Chem. 2004, 12, 507-521.
86. Poindexter G. S.; Bruce, M. A. LeBoulluec, K. L.; Monkovic, I.; Martin, S. W.; Parker, E.M.; Iben, L. G.; McGovern, R. T.; Ortiz, A. A.; Stanley, J. A. Mattson, G. K.; Kozlowski, M.; Arcuri, M.; Antal-Zimanyi, I. Dihydropyridine neuropeptide Y Y1 receptor antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 379-382.
87. Sato, N.; Shibata, T.; Jitsuoka, M.; Ohno, T.; Takahashi, T.; Hirohashi, T.; Kanno, T.; Iwaasa, H.; Kanatani, A.; Fukami, T. Synthesis and evaluation of substituted 4-alkoxy-2-aminopyridines as novel neuropeptide Y1 receptor antagonists. Bioorg. Med. Chem. Lett. 2004 14, 1761-1764.
88. Kanatani, A.; Kanno, T.; Ishihara, A.; Hata, M.; Sakuraba, A.; Tanaka, T.; Tsuchiya, Y.; Mase, T.; Fukuroda, T.; Fukami, T.; Ihara, M. The novel neuropeptide Y Y(1) receptor antagonist J-104870: A potent feeding suppressant with oral bioavailability. Biochem. Biophys. Res. Commun. 1999, 266, 88-91.
89. Kanatani, A.; Hata, M.; Mashiko, S.; Ishihara, A,; Okamoto, O.; Haga, Y.; Ohe, T.; Kanno, T.; Murai, N.; Ishii, Y.; Fukuroda, T.; Fukami, T.; Ihara, M. A typical Y1 receptor regulates feeding behaviors: Effects of a potent and selective Y1 antagonist, J-115814. Mol. Pharmacol. 2001, 59, 501-505.
90. Ishihara, A.; Kanatani, A.; Okada, M.; Hidaka, M.; Tanaka, T.; Mashiko, S.; Gomori, A.; Kanno, T.; Hata, M.; Kanesaka, M.; Tominaga, Y.; Sato, N. A.; Kobayashi, M.; Murai, T.; Watanabe, K.; Ishii, Y.; Fukuroda, T.; Fukami, T.; Ihara, M. Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist. Br. J. Pharmacol. 2002, 136, 341-346.
91. Di Fabio, R.; Giovannini, R.; Bertani, B.; Borriello, M.; Bozzoli, A.; Donati, D.; Falchi, A.; Ghirlanda, D.; Leslie, C. P.; Pecunioso, A.; Rumboldt, G.; Spada, S.; Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 1749-1752.
92. Leslie, C. P.; Fabio, R. D.; Bonetti, F.; Borriello, M.; Braggio, S.; Forno, G. D.; Donati, D.; Falchi, A.; Ghirlanda, D.; Giovanini, R.; Pavone, F.; Pecunioso, A.; Pentassuglia, G.; Pizzi, D. A.; Rumboldt, G.; Stasi, L. Novel carbazole derivatives as NPY Y1 antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 1043-1046
93. CEREP. Compounds based on four aromaric rings, preparation and uses thereof. WO2007071840, 2007.
94. Gerald, C.; Walker, M.W.; Criscione, L.; Gustafson, E.L.; Batzl-Hartmann, C.; Smith, K.E.; Vaysse, P.; Durkin, M.M.; Laz, T.M.; Linemeyer, D.L.; Schaffhauser, A.O.; Whitebread, S.; Hofbauer, K.G.; Taber, R.I.; Branchek, T.A.; Weinshank, R.L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996, 382, 168-171.
95. Larhammar, D.; Salaneck, E. Molecular evolution of NPY receptor subtypes. Neuropeptides 2004, 8, 141-151.
96. Criscione, L.; Rigollier, P.; Batzl-Hartmann, C.; Rueger, H.; Stricker-Krongrad, A.; Wyss, P.; Brunner, L.; Whitebread, S.; Yamaguchi, Y.; Gerald, C.; Heurich, R. O.; Walker, M. W.; Chiesi, M.; Schilling, W.; Hofbauer, K. G.; Levens, N. Food intake in freefeeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest. 1998, 102, 2136-2145.
97. Della-Zuana, O.; Revereault, L.; Beck-Sickinger, A.; Monge, A.; Caignard, D. H.; Fauchere, J. L.; Henlin, J. M.; Audinot, V.; Boutin, J. A.; Chamorro, S.; Feletou, M.; Levens, N. A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 628-639.
98. Block, M. H.; Boyer S.; Brailsford, W.; Brittain, D. R.; Carroll, D.; Chapman, S.; Clarke, D. S.; Donald, C. S.; Foot,e K. M.; Godfrey, L.; Ladner, A.; Marsham, P. R.; Masters, D. J.; Mee, C. D.; O'Donovan, M. R.; Pease, J. E.; Pickup, A. G.; Rayner, J. W.; Roberts, A.; Schofield, P.; Suleman, A.; Turnbull, A. V. Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J. Med. Chem. 2002, 45, 3509-3523.
99. Turnbull, A. V.; Ellershaw, L.; Masters, D. J.; Birtles, S.; Boyer, S.; Carroll, D.; Clarkson, P.; Loxham, S. J.; McAulay, P.; Teague, J. L.; Foote, K. M.; Pease, J. E.; Block, M. H. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 2002, 51, 2441-2449.
100. Kakui, N.; Tanaka, J.; Tabata, Y.; Asai, K.; Masuda, N.; Miyara, T.; Nakatani, Y.; Ohsawa, F.; Nishikawa, N.; Sugai, M.; Suzuki, M.; Aoki, K.; Kitaguchi, H. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9- isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor. J. Pharmaco. Exp. Ther. 2006, 317, 562-570.
101. Novartis AG. Condensed thiazolamines and their use as neuropeptide Y5 antagonists. WO01/64675A1, 2001.
102. Novartis AG. Selective NPY Y5 antagonists. US20077273880B2, 2007.
103. H. Lundbeck A/S. Selective NPY Y5 antagonists. US2008045524, 2008.
104. Sato, M.; Jitsuoka, M.; Ishikawa, S.; Nagai, K.; Tsuge, H.; Ando, M.; Okamoto, O.; Iwaasa, H.; Gomori, A.; Ishihara, A.; Kanatani, A.; Fukami, T. Discovery of substituted 2,4,4-triarylimidazole derivatives as a potent and selective neuropeptide Y Y5 receptor antagonists. Bioorg. Med. Chem. Lett. 2009, 19, 1670-1674.
105. Li, G.; Stamford, A. W.; Huang, Y.; Cheng, K-C.; Cook, J.;Farley, C.; Gao, J.; Ghibaudi, L.; Greenlee, W. J.; Guzzi, M.; van Heek, M.; Hwa, J. J.; Kelly, J.; Mullins, D.; Parker, E. M.; Wainhaus, S.; Zhang, X. Development of novel orally active ureido NPY Y5 receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 1146-1150.
106. Sakamoto, T.; Moriya, M.; Haga, Y.; Takahashi, T.; Shibata, T.; Okamoto, O.; Nonoshita, K.; Kitazawa, H.; Hidaka, M.; Gomori, A.; Iwaasa, H.; Ishihara, A.; Kanatani, A.; Fukami, T.; Gao, Y-D.; McNeil, D. J.; Yang, L. Identification of novel and orally spiroindoline NPY Y5 receptor antagonists. Bioorg. Med. Chem. Lett. 2009, 19, 1564-1568.
107. Ishihara, A.; Kanatani, A.; Mashiko, S.; Tanaka, T.; Hidaka, M.; Gomori, A.; Iwaasa, H.; Murai, N.; Egashira, S.; Murai, T.; Mitobe, Y.; Matsushita, H.; Okamoto, O.; Sato, N.; Jitsuoka, M.; Fukuroda, T.; Ohe, T.; Guan, X.; MacNeil, D. J.; Van der Ploeg, L. H.; Nishikibe, M.; Ishii, Y.; Ihara, M.; Fukami, T. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc. Natl. Acad. Sci. USA 2006, 103, 7154-7148.
108. Mashiko, S.; Ishihara, A.; Iwaasa, H.; Sano, H.; Ito, J.; A.; Oda, Z.; Moriya, R.; Matsushita, H.; Jitsuoka, M.; Okamoto, O.; MacNeil, D. J.; van der Ploeg, L. H. T.; Fukami, T.; Kanatani, A. A pairfeeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure. Mol. Pharmacol. 2007, 71, 602-608.
109. Erondu, N.; Gantz, I.; Musser, B.; Suryawanshi, S.; Mallick, M.; Addy, C.; Cote, J.; Bray, G.; Fujioka, K.; Bays, H.; Hollander, P.; Sanabria-Bohorquez, S. M.; Eng, W.; Langstrom, B.; Hargreaves, R. J.; Burns, H. D.; Kanatani, A.; Fukami, T.; MacNeil, D. J.; Gottesdiener, K. M.; Amatruda, J. M.; Kaufman, K. D.; Heymsfield, S. B. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006, 4, 275-282.
110. www.chemblink.com/products/342577-38-2.htm
111. www.shionogi.co.jp/iren/news/detail/e_090217.pdf
112. 3-36 physiologically inhibits food intake. Nature 2002, 418, 650-654
113. 3-36. Eng. J. Med. 2003, 349, 941-948.
114. 3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem. Biophys. Res. Commun. 2003, 311, 915-919.
115. 3-36 in rats with area postrema ablations. Peptides 2004, 25, 985-989.
116. Pittner, R. A.; Moore, C. X.; Bhavsar, S. P.; Gedulin, B. R.; Smith, P. A.; Jodka, C. M.; Parkes, D. G.; Paterniti, J. R.; Srivastava, V. P.; Young, A. A. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 963-971.
117. Chelikani, P. K.; Haver, A. C.; Reidelberger, R. D. Intravenous Infusion of Peptide YY(3-36) Potently Inhibits Food Intake in Rats. Endocrinology 2005, 146, 879-888.
118. 3-36 on Food Intake in Humans. Gastroenterology 2005, 129, 1430-1436.
119. (3-36) Inhibits Morning, but Not Evening, Food Intake and Decreases Body Weight in Rhesus Macaques. Diabetes 2005, 54, 3198-3204.
120. Moran, T. H.; Smedh, U.; Kinzig, K. P.; Scott, K. A.; Knipp, S.; Ladenheim, E. E. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288, R384-R388.
121. (3-36) on food intake. Brain Res. 2005, 1043, 139-144.
122. Gerald, C.; Walker, M. W.; Criscione, L.; Gustafson, E. L.; Batzl-Hartmann, C.; Smith, K. E.; Vaysse, P.; Durkin, M. M.; Laz, T. M.; Linemeyer, D. L.; Schaffhauser, A. O.; Whitebread, S.; Hofbauer, K. G.; Taber, R. I.; Branchek, T. A.; Weinshank, R. L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996, 382, 168-171.
123. Mullins, D.; Kirby, D.; Hwa, J.; Guzzi, M.; Rivier, J.; Parker, E. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol. Pharmacol. 2001, 60, 534-540.
124. Tschop, M.; Castaneda, T. R.; Joost, H. G.; Thone-Reineke, C.; Ortmann, S.; Klaus, S.; Hagan, M. M.; Chandler, P. C.; Oswald, K. D.; Benoit, S. C.; Seeley, R. J.; Kinzig, K. P.; Moran, T. H.; Beck-Sickinger, A. G.; Koglin, N.; Rodgers, R. J.; Blundell, J. E.; Ishii, Y.; Beattie, A. H.; Holch, P.; Allison, D. B.; Raun, K.; Madsen, K.; Wulff, B. S.; Stidsen, C. E.; Birringer, M.; Kreuzer, O. J.; Schindler, M.; Arndt, K.; Rudolf, K.; Mark, M.; Deng, X. Y.; Whitcomb, D. C.; Halem, H.; Taylor, J.; Dong, J.; Datta, R.; Culler, M.; Craney, S.; Flora, D.; Smiley, D.; Heiman, M. L. Does gut hormone PYY3-36 decrease food intake in rodents? (Reply). Nature 2004, 430, 165-166.
125. 3-36 Inhibits Food Intake in Mice through a Melanocortin-4 Receptor-Independent Mechanism. Endocrinology 2004, 145, 2585-2590.
126. DeCarr, L. B.; Buckholz, T. M.; Coish, P. D. G.; Fathi, Z.; Fisk, S. E.; Mays, M. R.; O'Connor, S. J.; Lumb, K. J. Identification of selective neuropeptide Y2 peptide agonists. Bioorg. Med. Chem. Lett. 2007, 17, 538-541.
127. Harris, J. M.; Chess, R. B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug. Disc. 2003, 2, 214-221.
128. Potter, E. K.; Barden, J. A.; McCloskey. M. J. D.; Selbie, L. A.; Tseng, A.; Herzog, H.; Shine, J. A novel neuropeptide Y analog, N-acetyl[Leu28,Leu31] neuropeptide Y-(24-36), with functional specificity for the presynaptic (Y2) receptor. Eur. J. Pharmacol. 1994, 267, 253-262.
129. Rist, B.; Zerbe, O.; Ingenhoven, N.; Scapozza, L.; Peers, C.; Vaughan, P. F. T.; McDonald, R. L.; Wieland, H. A.; Beck-Sickinger, A. G. Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor. FEBS Lett. 1996, 394, 169-173.
130. 2-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine. J. Med, Chem. 2000, 43, 3420-3427.
131. DeCarr. L. B.; Buckholz, T. M.; Milardo, L. F.; Mays, M. R.; Ortiz, A.; Lumb, K. J. A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg. Med. Chem. Lett. 2007, 17, 1916-1919.
132. Adrian, T. E.; Greenberg, G. R.; Besterman, H. S.; Bloom, S. R. Pharmacokinetics of pancreatic polypeptide in man. Gut 1978, 19, 907-909.
133. Balasubramaniam, A.; Mullins, D. E.; Lin, S.; Zhai, W.; Tao, Z.; Dhawan, V. C.; Guzzi, M.; Knittel, J. J.; Slack, K.; Herzog, H.; Parker, E. M. Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. J. Med. Chem. 2006, 49, 2661-2665.
134. Bodnar, R. J. Endogenous opioids and feeding behavior: A 30-year historical perspective. Peptides 2004, 25, 697-725.
135. Zhang, M.; Gosnell, B. A.; Kelley, A. E. Intake of high-fat food is selectively enhanced by Mu opioid receptor stimulation within the nucleus accumbens. J. Pharmacol. Exp. Ther. 1998, 285, 908-914.
136. Holtzman, S.G. Behavioral effects of separate and combined administration of naloxone and d-amphetamine. J. Pharmacol. Exp. Ther. 1974, 189, 51-60.
137. Glass, M. J.; Billington, C. J.; Levine, A. S. Opioids and food intake: distributed functional neural pathways? Neuropeptides 1999, 33, 360-368.
138. Yeomans, M. R.; Gray, R. W. Effects of naltrexone on food intake and changes in subjective appetite during eating: Evidence for opioid involvement in the appetizer effect. Physiol. Behav. 1997, 62, 15-21.
139. Fruzzetti, F.; Bersi, C.; Parrini, D.; Ricci, C.; Genazzani Andrea, R. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil. Steril. 2002, 77, 936-944.
140. Goodman, A. J.; Le Bourdonnec, B.; Dolle, R. E. Mu opioid receptor antagonists: Recent developments. ChemMedChem 2007, 2, 1552-1570.
141. Takeuchi, K.; Holloway, W. G.; McKinzie, J. H.; Suter, T. M.; Statnick, M. A.; Surface, P. L.; Emmerson, P. J.; Thomas, E. M.; Siegel, M. G.; Matt, J. E.; Wolfe, C. N.; Mitch, C. H. Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg. Med. Chem. Lett. 2007, 17, 5349-5352.
142. Takeuchi, K.; Holloway, W. G.; McKinzie, J. H.; Suter, T. M.; Statnick, M. A.; Surface, P. L.; Emmerson, P. J.; Thomas, E. M.; Siegel, M. G.; Matt, J. E.; Wolfe, C. N.; Mitch, C. H. Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg. Med. Chem. Lett. 2007, 17, 6841-6846.
143. Chappell, M. D.; Mitch, C. H.; Quimby, S. J.; Siegel, M. G. Opioid receptor antagonists. US Pat. Appl. 20080207701, 2008.
144. De La Torre, M. G.; Mitch, C. H.; Opioid receptor antagonists. US Pat. Appl. 20070287751, 2007.
145. Blanco-Pillado, M.-J.; Chappell, M. D.; De La Torre, M. G.; Buezo, N. D.; Fritz, J. E.; Holloway, W. G.; Matt, J. E.; Mitch, C. H.; Pedregal-Tercero, C.; Quimby, S. J.; Siegel, M. G.; Smith, D. R.; Stucky, R. D.; Takeuchi, K.; Thomas, E. M.; Wolfe, C. N. Diaryl ethers as opioid receptor antagonists. US Pat. Appl. 20080269296, 2008.
146. Bloxham, J.; Bradley, S. E.; Dupree, T. B.; Fry, P. T.; Hanrahan, P. E.; Krulle, T. M.; Procter, M. J.; Sambrook-Smith, C. P.; Schofield, K. L.; Smyth, D.; Stewart, A. J. W. Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders WO Pat. Appl. 2008142454, 2008.
147. Diaz, N.; Benvenga, M.; Emmerson, P.; Favors, R.; Mangold, M.; McKinzie, J.; Patel, N.; Peters, S.; Quimby, S.; Shannon, H.; Siegel, M.; Statnick, M.; Thomas, E.; Woodland, J.; Surface P.; Mitch, C. SAR and biological evaluation of novel trans-3,4- dimethyl-4-arylpiperidine derivatives as opioid antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 3844-3848.
148. 2C) receptor agonists as potential antiobesity agents. J. Med. Chem. 2006, 49, 4023-4034.
149. Hikiji, K.; Inoue, K.; Iwasaki, S.; Ichihara, K.; Kiriike, N. Local perfusion of mCPP into ventromedial hypothalamic nucleus, but not into lateral hypothalamic area and frontal cortex, inhibits food intake in rats. Psychopharmacology (Berlin) 2004, 174, 190-196.
150. 2C receptor mRNAs in mice prone, or resistant, to chronic high-fat diet-induced obesity. Brain Res. Mol. Brain Res. 2004, 127, 39-47.
151. Nichols, D. E. Hallucinogens. Pharmacol. Behav. 2004, 101, 131-181.
152. Setola, V.; Roth, B. L. Screening the Receptorome Reveals Molecular Targets Responsible for Drug-Induced Side Effects: Focus on "fen-phen". Expert Opin. Drug Metab. Toxicol. 2005, 1, 377-387.
153. 2C receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs. Drugs Future 2001, 26, 383-393.
154. 2C receptor modulators: progress in development of new CNS medicines. Annu. Rep. Med. Chem. 2002, 37, 21-30.
155. 2C receptor agonists as potential drugs for the treatment of obesity. Curr. Top. Med. Chem. 2003, 3, 885-897.
156. 2C receptor agonists. Expert Opin. Ther. Pat. 2003, 13, 1691-1705.
157. 2C receptors as a potential therapeutic target for the design antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 59-67.
158. Halford, J. C. G.; Harrold, J. A.; Lawton, C. L.; Blundell, J. E. Serotonin (5-HT) drugs: Effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets 2005, 6, 201-213.
159. 2C receptor agonists: Potential for the treatment of obesity. Mol. Interventions 2005, 5, 282-291.
160. 2C receptor agonist for the treatment of obesity. J. Med. Chem., 2008, 51, 305-313.
161. 2C receptor ligands and uses. WO Pat. Appl. 2007084622, 2007.
162. 2C receptor agonist. WO Pat. Appl. 2007028132, 2007.
163. 2C receptor agonist. WO Pat. Appl. 2007028083, 2007.
164. 2C receptor agonist. WO Pat. Appl. 2007028082, 2007.
165. 2C receptor. J. Med. Chem. 2007, 50, 1365-1379.
166. 2C receptor agonist. Bioorg. Med. Chem. Lett. 2006, 16, 4130-4134.
167. 2C receptor agonists. Bioorg. Med. Chem. Lett. 2006, 16, 1207-1211.
168. Bentley, J. C.; Sleight, A. J.; Marsden, C. A.; Fone, K. C. F. 5-HT6 antisense oligonucleotide i.c.v. affects rat performance in the water maze and feeding. J. Psychopharmacol. 1997, 11, A64.
169. Caldirola, P. 5-HT6 receptor antagonism: A novel mechanism for the management of obesity. SMI Conf. obesity and related disorders (Feb 17-18, London) from: www.iddb3.com, 2003.
170. Woolley, M. L.; Bentley, J. C.; Sleight, A. J.; Marsden, C. A.; Fone, K. C. F. A role for 5-HT6 receptors in retention of spatial learning in the water maze and feeding. Neuropharmacology 2001, 41, 210-219.
171. Bentley, J. C.; Bourson, A.; Boess F. G.; Fone, K. C. F.; Marsden, C. A.; Petit, N.; Nadine Petit and Sleight, A. J. Investigation of stretching behavior induced by the selective 5-HT6 receptor antagonist Ro 04-6790 in rats. Br. J. Pharmacol. 1999, 126, 1537-1542
172. Svartengren, J.; Öhman, B.; Edling, N.; Svensson, M.; Fhölenhag, K.; Axelsson-Lendin, P.; Klingström, G.; Larsson, C. The serotonin 5-HT6 receptor antagonist BVT-5182 reduces body weight of high fat diet-induced mice. Int. J. Obes. 2003, 27(Suppl.1), Abst. T1, P1-094.
173. Woolley M.L.; Marsden C.A.; Fone K.C.F. 5-HT6 receptors. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 59-79.
174. Holenz, J.; Pauwels, P. J.; Diaz, J. L.; Merce, R.; Codony, X.; Buschmann, H. Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov. Today 2006, 11, 283-299.
175. Heal, D. J.; Smith, S. L; Fisas, A.; Codony, X.; Buschmann, H. Selective 5-HT6 receptor: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther. 2008, 117, 207-231.
176. Fisas-Escasany, M.A., Buschmann, H.D. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain, EP Patent Application, 2018861.
177. Angbrant, J.; Brandt, P.; Ringom, R.; Lindqvist, B. Tricyclic isoquinoline derivatives for the treatment of obesity. WO Pat. Appl. 2008, 2008110598.
178. 3) of histamine receptor. Nature 1983, 302, 832-837.
179. Itoh, E.; Fujimiya, M.; Inui, A. Thioperamide, a histamine H3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol. Psychiatry 1999, 45, 475-481.
180. 3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci., 2001, 69, 469-478.
181. Yoshimo, R.; Miyamoto, Y.; Shimamura, K.; Ishihara, A.; Takahashi, K.; Kotani, H.; Chen, A. S.; Chen, H. Y.; Macneil, D. J.; Kanatani, A.; Tokita, S. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc. Natl. Acad. Sci. USA 2006, 103, 13866-13871.
182. Takahashi, K.; Suwa, H.; Ishikawa, T.; Kotani, H. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J. Clin. Invest., 2002, 110, 1791-1799.
183. Marlon C.; Robert, A.; Lawrence, B.; Ramin, F.; Chen, Z.; Arthur, A.H. Medicinal Chemistry and Biological Properties of Non-Imidazole Histamine H3 Antagonist. Mini-reviews in Medicinal Chemistry, 2004, 4, 979-992.
184. Mike, E. P.; Ganellin C. R. Histamine and its receptors. Br. J. Pharmacol. 2006, 147, S127-S135
185. Takayuki, M.; Hironobu, Y. Neuronal Histamine and Histamine Receptors in Food Intake and Obesity. Mini-Rev. Med. Chem. 2007, 7, 821-825.
186. Nettekoven, M.; Roche, O. (Indol-4-yl) or (indol-5-yl)-piperazinylmethanone derivatives for the treatment of obesity. WO Pat. Appl. 2008095820, 2008.
187. Nettekoven, M.; Roche, O. 1H-Indol-6-yl-piperazin-1-yl-methaonone-derivatives for use as H3 receptor modulators. WO Pat. Appl. 2008015125, 2008.
188. Berke, H.; Howard, H. R. Jr. Azabicyclic ether histamine-3 antagonists. WO Pat. Appl. 2007138431, 2007.
189. Howard, H. R. Jr. 2-Pyrrolidine indane derivatives as histamine-3 receptor antagonists. WO Pat. Appl. 2007099423, 2007.
190. Solomon, D. M.; Aslanian, R. G.; Berlin, M. Y.; De Lera Ruiz, M.; Mccormick, K. D.; Mutahi, M. W.; Tom, W. C. Substituted aniline derivatives useful as histamine H3 antagonists. WO Pat. Appl. 2007075688, 2007.
191. Mutahi, M. W.; Aslanian, R. G.; Berlin, M. Y.; Boyce, C. W.; De Lera Ruiz, M.; Mccormick, K. D.; Solomon, D. M.; Vaccaro, H. A.; Zheng, J.; Purakkattle, B. J.; Yu, Y.; Zhou, W.; Zhu, X. Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists. WO Pat. Appl. 2007075629, 2007.
192. Nelson, D. L.; Gehlert, D. R. Obesity/Metabolic Syndrome Overview. Comprehensive medicinal chemistry II, John B Taylor, J. B.; Triggle, D. J. Vol 6, 2007, 381-387.
193. Glick, S. D.; Haskew, R. E.; Maisonneuve, I. M.; Carlson, J. N.; Jerussi, T. P. Enantioselective behavioral effects of sibutramine metabolites. Eur. J. Pharmacol. 2000, 397, 93-102
194. Bray, G. A.; Greenway, F. L. Current and Potential Drugs for Treatment of Obesity. Endocrinol. Rev. 1999, 20, 805-875
195. Stahl, S. M.; Pradko, J. F.; Haight, B. R.; Modell, J. G.; Rockett, C. B.; Learned-Coughlin, S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J. Clin. Psychiat. 2004, 6(4), 159-166.
196. Drahl, C. Weighing Options. C&EN, April 13, 2009, 11-16.
197. Bara-Jimenez, W.; Dimitrova, T.; Sherzai, A.; Favit, A.; Mouradian, M. M.; Chase, T. N. Effect of monoamine reuptake inhibitor NS2330 in advanced Parkinson's disease. Movement Disord. 2004, 19(10), 1183-1186.
198. Astrup, A.; Meier, D. H.; Mikkelsen, B. O.; Villumsen, J. S.; Larsen, T. M. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity 2008, 16(6), 1363-9.
199. Scheel-Kruger, J.; Moldt, P.; Watjen, F. Tropane-derivatives, their preparation and use. US Patent 6395748.
200. Scheel-Kruger, J.; Moldt, P.; Watjen, F. Tropane-derivatives, their preparation and use. US Patent 6288079.
201. Larsen, M. H.; Rosenbrock, H.; Sams-Dodd, F.; Mikkelsen, J. D. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine reuptake inhibitor tesofensine. Eur. J. Pharmacol. 2007, 555(2-3), 115-121.
202. Lehr, T.; Staab, A.; Tillmann, C.; Trommeshauser, D.; Raschig, A.; Schaefer, H. G.; Kloft, C. Population pharmacokinetic modelling of NS2330 (tesofensine) and its mahor metabolite in patients with Alzheimer's disease. Br. J. Clin. Pharmacol. 2007, 64(1), 36-48.
203. Lehr, T.; Staab, A.; Tillmann, C.; Nielsen, E. O.; Trommeshauser, D.; Schaefer, H. G.; Kloft, C. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: A pharmacokinetic-pharmacodynamic modeling approach. Br. J. Pharmacol. 2008, 153(1), 164-174.
204. Astrup, A.; Madsbad, S.; Breum, L.; Jenssen, T. J.; Kroustrup, J. P.; Larsen, T. M. Effect of tesofensine on bodyweight loss, body composition, and quality of life on obese patients: A randomized, double-blind, place-controlled trial. Lancet 2008, 372, 1906-1913.
205. Cooke, D.; Bloom, S. The obesity pipeline: Current strategies in the development of anti-obesity drugs. Nat. Rev. Drug Discov. 2006, 5, 919-931.
206. Bray, A. B.; Greenway, F. L. Current and potential drugs for treatment of obesity. Endocr. Rev. 1999, 20(6), 805-875.
207. Hofbauer, K. G.; Nicholson, J. R.; Boss, O. The obesity epidemic: current and future pharmacological treatments. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 565-592.
208. Padwal, R. S.; Majumdar, S. R. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007, 369, 71-77.
209. Chaput, J. P.; Tremblay, A. Current and novel approaches to the drug therapy of obesity. Eur. J. Clin. Pharmacol. 2006, 62, 793- 803.
210. Rubio, M. A.; Gargallo, M.; Millá, A. I.; Moreno, B. Drugs in the treatment of obesity; sibutramine, orlistat and rimonabant. Publ. Health Nutr. 2007, 10(10A), 1200-1205.
211. Drew, B. S.; Dixon, A. F.; Dixon, J. B. Obesity management: Update on orlistat. Vasc. Health Risk Manag. 2007, 3(6), 817-821.
212. Padwal, R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr. Opin. Investig. Drugs, 2008, 9(4), 414-421.
213. Kopelman, P.; Bryson, A.; Hickling, R.; Rissanen, A.; Rossner, S.; Toubro, S.; Valensi, P. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int. J. Obes. 2007, 31(3), 494-499.
214. Halford, J. C. G. Obesity drugs in clinical development. Curr. Opin. Investig. Drugs 2006, 7(4), 312-318.
215. Melnikova, I.; Wages, D. Anti-obesity therapies. Nat. Rev. Drug Discov. 2006, 5(5), 369-370.
216. Idris, I.; Donnelly, R. Sodium-glucose co-transporter-2 inhibitors: An emerging new class of oral antidiabetic drug. Diabetes Obes. Metab. 2009, 11, 79-88.
217. Washburn, W. N. Development of the renal glucose reabsorption inhibitors: A new mechanism for the pharmacotherapy of diabetes mellitus type 2. J. Med. Chem. 2009, 52(7), 1785-1794.
218. Jabbour, S. A.; Goldstein, B. J. Sodium glucose co-transporter 2 inhibitors: Blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 2008, 62(8), 1279-1284.
219. Arch, J. R. S. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: Perspectives from β3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Parmacol. 2008, 378(2), 225-240.
220. Harada, H.; Hirokawa, Y.; Suzuki, K.; Hiyama, Y.; Oue, M.; Kawashima, H.; Kato, H.; Yoshida, N.; Furutani, Y.; Kato, S. Discovery of a novel and potent human and rat β3-adrenergic receptor agonist, [3-[(2R)-(3-chlorophenyl)-2-hydroxyethyl] amino]propyl]-1H-indol-7-yloxyacetic acid. Chem. Pharm. Bull. 2005, 53(2), 184-198.
221. Sawa, M.; Harada, H. Recent developments in the design of orally bioavailable β3-adrenergic receptor agonists. Curr. Med. Chem. 2006, 13, 25-37.
222. Dow, R. L.; Paight, E. S.; Schneider, S. R.; Hadcock, J. R.; Hargrove, D. M.; Martin, K. A.; Maurer, T. S.; Nardone, N. A.; Tess, D. A.; DaSilva-Jardine, P. Potent and selective, sulfamide-based human β3-adrenergic receptor agonists. Bioorg. Med. Chem. Lett. 2004, 14, 3235-3240.
223. van Baak, M. A.; Hul, G. B. J.; Toubro, S.; Astrup, A.; Gottesdiener, K. M.; DeSmet, M.; Saris, W. H. M. Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men. Clin. Pharmacol. Ther. 2002, 71(4), 272-279.
224. Lafontaine, J. A.; Day, R. F.; Dibrino, J.; Hadcock, J. R.; Hargrove, D. M.; Linhares, M.; Martin, K. A.; Maurer, T. S.; Nardone, N. A.; Tess, D. A.; DaSilva-Jardine, P. Discovery of potent and orally bioavailable heterocycle-based β3-adrenonergic receptor agonists, potential therapeutics for the treatment of obesity. Bioorg. Med. Chem. Lett. 2007, 17, 5245-5250.
225. Yanagisawa, T.; Sato, T.; Yamada, H.; Sukegawa, J.; Nunoki, K. Selectivity and potency of agonists for the three subtypes of cloned human β-adrenoceptors expressed in Chinese hamster ovary cells. Tohoku J. Exp. Med. 2000, 192, 181-193.
226. Arch, J. R. S. β-Adrenoceptor agonists: Potential, pitfalls and progress. Eur. J. Pharmacol. 2002, 440, 99-107
227. Redman, L. M.; Jonge, L.; Fang, X.; Gamlin, B.; Recker, D.; Greenway, F. L.; Smith, S. R.; Ravussin, E. Lack of an effect of a novel β3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: A double-blind, placebo-controlled randomized study. J. Clin. Endocrinol. Metab. 2007, 92, 527-531.
228. Kusunoki, J.; Kanatani, A.; Moller, D. E. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. Endocrine, 2006, 29(1), 91-100.
229. Clapham, J. C.; Arch, J. R. S. Thermogenic and metabolic antiobesity drugs: Rationale and opportunities. Diabetes Obes. Metab. 2007, 9, 259-275.
230. Bultin, R. J.; Plowright, A. Substituted 5-phenylamino-1,3,4-oxadiazol-2-yl carbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase. WO2007138311, 2007.
231. Butlin, R. J.; Davies, R. McCoull, W. Chemical compounds. WO2007141502, 2007.
232. Bennett, S. N. L.; Butlin, R. J.; Plowright, A. Compounds for the inhibition of DGAT1 activity. WO2007141545, 2007.
233. Lee, H. S.; Lee, K.; Lee, J. J.; Kim, Y. K.; Rho, M.-C.; Lee, J. H.; Hong, Y. S.; Park, H.-R. Lee, C.-H.; Choi, Y. Composition for the prevention and treatment of metabolic disorder containing benzazole derivatives as an active ingredient. WO2008039008, 2008.
234. Dobrzyn, A.; Ntambi, J. M. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes. Rev. 2005, 6(2), 169-174.
235. Xin, Z.; Zhao, H,; Serby, M. D.; Liu, B.; Liu, M.; Szczepankiewicz, B. G.; Nelson, L. T. J.; Smith, H. T.; Suhar, T. S.; Janis, R. S.; Cao, N.; Camp, H. S.; Collins, C. A.; Sham, H. L.; Surowy, T. K.; Liu, G. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. Bioorg. Med. Chem. Lett. 2008, 18(15), 4298-4302.
236. Flowers, M. T.; Ntambi, J. M. Stearoyl-CoA desaturase and its relation to high-carbohydrate diets and obesity. Biochim. Biophys. Acta 2009, 1791(2), 85-91.
237. Ramtohul, Y. K.; Li, C. S.; Leclerc, J.-P. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO2009012573, 2009.
238. Leger, S.; Deschenes, D.; Fortin, R.; Isabel, E.; Powell, D. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO2008141455, 2008.
239. Leblanc, Y.; Powell, D.; Ramtohul, Y. K.; Leger, S. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delata-9 desaturase. WO2008089580, 2008.
240. Lachance, N.; Li, C. S.; Leclerc, J.-P.; Ramtouhul, Y. K. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase. WO2008128335, 2008.
241. Liu, G.; Lynch, J. K.; Freeman, J.; Liu, B. Xin, Z.; Zhao, H.; Serby, M. D.; Kym, P. R.; Suhar, T. S.; Smith, H. T.; Cao, N.; Yang, R.; Janis, R. S.; Krauser, J. A.; Cepa, S. P.; Beno, D. W. A.; Sham, H. L.; Collins, C. A.; Surowy, T. K.; Camp, H. S. Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors. J. Med. Chem. 2007, 50(13), 3086-3100.
242. Dales, N.; Zhang, Z.; Fonarev, J.; Fu, J.; Kamboj, R.; Kodumuru, V.; Pokrovskaia, N.; Sun, S. 2-Substituted 5-membered heterocycles as SCD inhibitors. WO2008074835, 2008.
243. Dales, N.; Zhang, Z.; Fonarev, J.; Fu, J.; Kamboj, R.; Kodumuru, V.; Liu, S.; Pokrovskaia, N.; Raina, V.; Sun, S. Organic compounds. WO2008127349, 2008.
244. Koltun, D.; Parkhill, E.; Boze, M.; Zablocki, J.; Vasilevich, N.; Glushkov, A.; Cole, A.; Mayboroda, E.; Chisholm, J. 3-Hydroquinazolin-4-one derivatives for use as stearoyl CoA desaturase inhibitors. WO2008127615, 2008.
245. Zilbershtein, T.; Cole, A.; Zablocki, J.; Koltun, D.; Chisholm, J.; Glushkov, A.; Vasilevich, N.; Henderson, I.; Lin, T.; Parkhill, E. Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors. WO2008123891, 2008.
246. Neels, J. G.; Olefsky, J. M. A new way to burn fat. Science 2006, 312, 1756-1758.
247. Tong, L.; Harwood, H. J. Acetyl-coenzyme A carboxylase: Versatile targets for drug discovery. J. Cell Biochem. 2006, 99(6), 1476-1488.
248. Tong. L. Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery. Cell Mol. Life Sci. 2005, 62(16), 1784-1803.
249. Scriabine, A. HDL cholesterol: Metabolic pathways and drug developments fifth annual international conference of the knowledge foundation. Cardiovasc. Drug Rev. 2004, 22(2), 147-153.
250. Gu, Y. G.; Weitzberg, M.; Clark, R. F.; Xu, X.; Li, Q.; Zhang, T.; Hansen, T. M.; Liu, G.; Xin, Z.; Wang, X.; Wang, R.; McNally, T.; Camp, H.; Beutel, B. A.; Sham, H. L. Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors. J. Med. Chem. 2006, 49(13), 3770-3773.
251. Gu, Y. G.; Weitzberg, M.; Clark, R. F.; Xu, X.; Li, Q.; Lubbers, N. L.; Yang, Y.; Beno, D. W. A.; Widomski, D. L.; Zhang, T.; Hansen, T. M.; Keyes, R. F.; Waring, J. F.; Carroll, S. L.; Wang, X.; Wang, R.; Healan-Greenberg, C. H.; Blomme, E. A.; Beutel, B. A.; Sham, H. L.; Camp, H. S. N-{3-[2-(4-Alkoxyphenoxy)thiazol-5-yl] -1-methylprop-2-ynyl}carboxy derivatives as acetyl-CoA carboxylase inhibitors improvement of cardiovascular and neurological liabilities via structural modifications. J. Med. Chem. 2007, 50(5), 1078-1082.